FutureMeds

Study Participant Identification

How can my Pharmacy be involved?

FutureMeds conduct clinical trials to develop new and improved medicines for the treatment of various medical conditions, such as Hypertension, Weight-loss, COPD, Lipids/cholesterol, MASH, Liver fibrosis, and Vaccines

3 levels of involvement: Pharmacies can be work with us across some or all of the levels below:

Clinical Trial Awareness - posters/flyers/leaflets on display in Pharmacy
Signposting – provide flyer/leaflet on per patient basis
Participant identification - via database search (see typical workflow below):



[1] Research Ethics Committee approved text & letter wording & flyers. [2] £200 PIC agreement fee, £150 for a participant that attends screening visit, £200 for any participant who is randomised into a study.

For participants added to FutureMeds database from initial Pharmacy identification but take part in a study at a later date, Screening fee and Randomisation fee still payable. Referral source is tracked for all participants.

FutureMeds
Tomorrow's medicines today

Study Information Sheet

ZENITH is a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Summary of Study Goal

The primary objective of the study is to evaluate the efficacy of zilebesiran in patients with uncontrolled hypertension and with either established CVD or high risk for CVD by demonstrating the ability of zilebesiran to reduce the risk of CV death, nonfatal MI, nonfatal stroke, or HF events (hospitalization for HF or urgent HF visit).

Key Inclusion

- Established CV disease & 18+ – At least one of the following: Coronary Artery Disease, or Peripheral Artery Disease, or Cerebrovascular Disease.
- Or, High Risk for CV Disease & 55+ - Age >70, Current Smoker, Type 1/ Type 2 Diabetes, BMI ⩾ 30, eGFR <60 mL/min/1.73m2 during screening
- Treated Hypertension on stable therapy
- Seated automated mean office SBP ⩾145 mmHg and <180 mmHg during the Screening period and ⩾140 mmHg and <180 mmHg on Day 1 (before randomization) with measurements taken at least 7 days apart

Key Exclusion

- Known history of secondary hypertension
- Hospitalisation for HF within 60 days
- HbA1c >10% within 60 days
- Known weight loss >10% within 60 days
- History of clinically significant CV event within 60 days
- Severe Aortic Stenosis

Search Criteria

Patients on any of the following medications:
Thiazide and Thiazide like:

- Bendroflumethiazide
- Indapamide
- Hydrochlorothiazide
- Chlorthalidone
- Metolazone

Loop Diuretics:

- Furosemide
- Bumetanide
- Torsemide

Referral Agreement

- **A £200.00** payment to the Referral Site to agree to this contract and undertake the promotional activities
- **A further £150.00** for each patient that the Referral Site refers to FutureMeds, who meets the inclusion/exclusion and **screens** onto study with a patient medical summary
- **A payment of £200.00** for every patient the Referral Site refers who meets the inclusion/exclusion criteria and **enrols** onto the study

Middlefield Centre, University Hospital of North Tees, Hardwick Road, TS19 8PE

Contact

If you would like to know more about this study or how FutureMeds collaborates with local organisations in the community, please contact:

Anthony Waine - Clinical Relations Specialist
01642 843 780
anthony.waine@futuremeds.com
www.futuremeds.co.uk